
Pulmonx (LUNG) Stock Forecast & Price Target
Pulmonx (LUNG) Analyst Ratings
Bulls say
Pulmonx Corporation demonstrated a strong financial position with a strengthened balance sheet, highlighted by securing up to $60 million in committed capital through a new five-year interest-only credit facility, extending debt maturity to 2031. The company's Q3 2025 revenue reached $21.5 million, reflecting a 5% year-over-year increase, with a solid gross margin of 75% and an improvement in gross profit to $17.5 million with a gross margin of 78%. Additionally, management's focus on cost restructuring, improved margins, and strategies to expand the eligible patient pool for treatment supports a positive outlook for sustainable growth and profitability.
Bears say
Pulmonx's financial performance in 2025 reveals modest annual growth of 8% with total revenue reaching $90.5 million; however, the fourth quarter exhibited a decline in revenue to $22.6 million, primarily due to weaker U.S. sales. The company experienced a significant decrease in cash, cash equivalents, and marketable securities, totaling $69.8 million at year-end, which marked a $32 million decline year over year, and it anticipates further cash depletion of approximately $23 million during 2026 without additional financing. Lastly, with operating expenses at $120.8 million and a net loss of $54 million, these factors contribute to a negative outlook for Pulmonx’s financial stability and operational effectiveness.
This aggregate rating is based on analysts' research of Pulmonx and is not a guaranteed prediction by Public.com or investment advice.
Pulmonx (LUNG) Analyst Forecast & Price Prediction
Start investing in Pulmonx (LUNG)
Order type
Buy in
Order amount
Est. shares
0 shares